...
首页> 外文期刊>BMC Musculoskeletal Disorders >Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures
【24h】

Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures

机译:特立帕肽对骨质疏松性股骨颈骨折患者非水泥双极半髋置换的影响

获取原文
           

摘要

Background For osteoporotic femoral neck fractures, suitable bone-implant stability is critical for pain relief, early return to daily activities and reduction of complications. Teriparatide (parathyroid hormone [PTH1-34]) can improve bone-implant stability in some basic studies. However it’s use in osteoporotic femoral neck fractures treated by cementless hemiarthroplasties for the beneficial effects on bone-implant stability is sparse in the literature. The aim of this study was to determine if post-operative teriparatide administration can reduce femoral stem migration and improve early functional recovery and health-related quality of life (HRQoL). Methods Between 2010 and 2014, patients with osteoporotic femoral neck fracture who underwent cementless bipolar hemiarthroplasty were included into this retrospective cohort study. Group A included patients treated with cementless bipolar hemiarthroplasty only; Group B patients had additional teriparatide. Demographic data, complications, radiographic and functional outcomes as well as health-related quality of life (HRQoL) were compared. Results There were 52 hips in group A (no teriparatide) and 40 hips in group B (patient who received teriparatide). The subsidence of the femoral stem tended to be significantly decreased in the teriparatide group at 6 and 12?weeks post-operatively ( p =?0.003 and p =?0.008, respectively). The Harris Hip Score (HHS) increased significantly from pre-operation to 6?weeks post-operatively and thereafter up to one year in both groups. However, there were no significant differences in terms of subsequent fracture, mortality, HHS, and HRQoL between two groups during the entire study period. Conclusions Teriparatide significantly reduces the subsidence of the cementless femoral stem in elderly patients in the early post-operative period, but this benefit does not reflect better functional outcomes and HRQoL. Further prospective randomized large-scale cohort study is warranted for evidence-based recommendations.
机译:背景对于骨质疏松性股骨颈骨折,合适的骨植入物稳定性对于缓解疼痛,尽早恢复日常活动和减少并发症至关重要。在一些基础研究中,特立帕肽(甲状旁腺激素[PTH1-34])可以改善骨植入物的稳定性。然而,在文献报道中,这种技术在通过非骨水泥半髋成形术治疗的骨质疏松性股骨颈骨折中有用,因为它对骨植入物稳定性具有有益作用。这项研究的目的是确定术后特立帕肽治疗是否可以减少股骨干迁移并改善早期功能恢复和健康相关的生活质量(HRQoL)。方法回顾性研究2010年至2014年间接受非骨水泥性双极半髋置换的骨质疏松性股骨颈骨折患者。 A组包括仅接受非骨水泥双极半髋成形术治疗的患者。 B组患者还有特立帕肽。比较了人口统计学数据,并发症,影像学和功能结局以及与健康相关的生活质量(HRQoL)。结果A组(无特立帕肽)髋部52髋,B组(接受特立帕肽患者)髋部40髋。特立帕肽组术后6周和12周时,股骨干的下陷趋势明显减少(分别为p = 0.003和p = 0.008)。从手术前到术后6周,Harris Hip评分(HHS)均显着提高,之后两组均提高到一年。但是,在整个研究期间,两组之间在随后的骨折,死亡率,HHS和HRQoL方面无显着差异。结论Teriparatide可显着减少老年患者术后早期非骨水泥型股骨柄的下陷,但这种益处并未反映出更好的功能结局和HRQoL。需要进行进一步的前瞻性随机大规模队列研究,以提供循证推荐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号